H E4、CA125及CA72-4在子宫内膜异位症及卵巢癌中的诊断差异研究

摘要

目的：寻找互补的生物标记物来帮助鉴别诊断子宫内膜异位症或其他卵巢良性肿瘤与卵巢癌。方法收集50例健康女性、17例良性卵巢肿瘤、57例子宫内膜异位症及39例卵巢癌患者的血液样本，并分析血清中的CA125、HE4及CA72-4的含量。结果血清CA125含量在子宫内膜异位症及卵巢癌患者血清中升高，但在其他卵巢良性肿瘤未见明显变化。HE4仅在卵巢癌患者血清中显著升高（P＜0．05），在子宫内膜异位症及卵巢良性肿瘤患者中未增加。此外，CA72-4在66．7％的卵巢癌患者血清中上升，与子宫内膜异位症相比，也有显著统计学意义（P＜0．05）。结论在血清CA125水平较高的女性中，通过检测 HE4及 CA72-4水平可帮助鉴别诊断子宫内膜异位症与卵巢癌。%Objective To search a panel of complementary biomarkers that could be helpful in the differential diag-nosis between ovarian endometriosis or other ovarian benign masses and ovarian cancer.Methods Blood samples from 50 healthy women,17 patients with benign ovarian tumors,57 patients with ovarian endometriosis and 39 patients with ovarian cancer were analyzed and serum values were measured for the following biomarkers:CA125,HE4 and CA72-4. Results Serum CA125 concentration was elevated in both patients with ovarian endometriosis and ovarian cancer but not in patients with other benign ovarian masses.HE4 was never increased in patients with endometriosis or benign masses whereas it was significantly higher in all patients with ovarian cancer (P<0.05).A marked difference in CA72-4 values was observed between women with ovarian cancer (67%)and those with endometriosis (P<0.05).Conclusion The results of the study suggest that HE4 and CA72-4 determination is the best approach to confirm the benign na-ture of ovarian endometriosis in women with high CA125 levels.